NCT02910466 - A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 27, 2016

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions

Chronic HypoparathyroidismHypoparathyroidism

Interventions

DRUG

rhPTH(1-84)

Participants will receive 25, 50, 75, and 100 microgram (mcg) of rhPTH(1-84) subcutaneous injection to the thigh via a multidose pen injector device once daily for 36 months. The dose will be individualized based on Albumin-corrected Serum Calcium (ACSC) and 24-hour calcium urinary excretion to achieve a serum calcium level in the lower half of the normal range.

Trial Locations (1)

10032

Columbia University Medical Center, New York